Paliperidone Ratiopharm (Paliperidone Palmitate)

Paliperidone Palmitate, the active ingredient in Paliperidone Ratiopharm, is a atypical antipsychotic presented as a long‑acting injectable suspension for intramuscular use. It treats schizophrenia and schizoaffective disorder in adults and adolescents when oral therapy is insufficient or adherence is a concern.

GNH USA supplies Paliperidone Ratiopharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Paliperidone Ratiopharm is an atypical antipsychotic indicated for disorders that involve dopaminergic and serotonergic dysregulation. - Schizophrenia: reduces the frequency and severity of psychotic episodes and supports long‑term symptom control. - Schizoaffective disorder: alleviates both mood and psychotic symptoms, helping maintain functional stability. - Maintenance therapy for patients who have responded to oral paliperidone but need a long‑acting formulation to improve adherence.

Adverse reactions to paliperidone palmitate vary in frequency and severity.

Common Side Effects: - Injection site pain or erythema: mild discomfort at the administration site. - Weight gain: gradual increase in body mass index. - Headache: transient cranial discomfort. - Restlessness (akathisia): inner sense of motor restlessness. - Fatigue: generalised tiredness. - Nasal congestion: mild upper‑respiratory irritation.

Serious or Rare Side Effects: - Neuroleptic malignant syndrome: life‑threatening reaction with fever, rigidity and autonomic instability. - Tardive dyskinesia: persistent involuntary movements, often of the face. - Seizures: especially in patients with pre‑existing seizure disorders. - Hyperglycaemia: significant rise in blood glucose levels. - Orthostatic hypotension: marked drop in blood pressure upon standing. - Severe allergic reaction: anaphylaxis or angio‑edema requiring immediate medical attention.

When prescribing paliperidone palmitate, clinicians should consider several safety aspects. - Cardiovascular assessment: evaluate for QT‑interval prolongation and existing heart disease. - Metabolic monitoring: regularly check weight, glucose and lipid profiles. - Movement disorders: watch for early signs of akathisia or tardive dyskinesia. - Pregnancy and lactation: avoid use unless benefits outweigh potential risks. - Renal function: adjust expectations in patients with severe impairment. - Store at room temperature: keep in original packaging, protect from moisture and direct sunlight.

Paliperidone palmitate may interact with other medicines, requiring vigilance.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase paliperidone exposure. - CNS depressants (e.g., benzodiazepines, opioids): additive sedation and respiratory depression. - Antihistamines with anticholinergic properties: heightened anticholinergic burden.

Moderate Interactions (Monitor Closely):\n- CYP2D6 substrates (e.g., metoprolol, codeine): potential alteration in plasma levels. - Drugs that prolong QT interval (e.g., certain antiarrhythmics, fluoroquinolones): monitor cardiac rhythm. - Lithium: may increase risk of neuro‑leptic malignant syndrome. - Antihypertensives: possible additive blood‑pressure lowering effect.